Abstract: Prochiral ketones are enantioselectively reduced to chiral secondary alcohols with a compound having the formula I: where, the two R2 groups are identical and are each a substituted or unsubstituted, aryl, alkyl, cycloalkyl or aralkyl group; and R3 is a hydrogen atom or a substituted or unsubstituted, alkyl, aryl, aralkyl or alkoxy group; wherein the substituents on the R2 and R3 groups are substantially non-reactive.

Abstract: The present invention discloses novel substituted imidazole compounds which have dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, inflammatory and CNS-related diseases and others.

Abstract: A topically acceptable aqueous pour-on formulation adapted for localized external application to an animal, which format includes an effective amount of a water insoluble insect growth regulator (IGR), a suspending agent, a surfactant or mixture of surfactants, and an aqueous carrier.

Abstract: The present invention discloses antibiotic-excluded compositions and methods to treat non-infective sinusitis and/or otitis media. The compositions comprise a therapeutically effective amount of an anticholinergic antihistamine or a pharmaceutically acceptable salt or solvate thereof; and (ii) a pharmaceutically acceptable carrier, and the methods comprise administering the same.

Abstract: In one embodiment, the present invention discloses a method and pharmaceutical composition for lowering serum cholesterol in a patient. The method comprises administering to the patient a pharmaceutical composition comprising a therapeutically effective cholesterol lowering amount of an imidazole.

Abstract: The present invention is directed towards a pharmaceutical composition useful for the treatment of allergic rhinitis, asthma and related disorders. In one embodiment, the composition comprises, in combination, a therapeutically effective amount of at least one neurokinin antagonist, and a therapeutically effective amount of at least one 5-lipoxygenase inhibitor.

Abstract: The present invention is directed towards a pharmaceutical composition useful for the treatment allergic rhinitis, asthma and related disorders. In one embodiment, the composition comprises, in combination, a therapeutically effective amount of at least one neurokinin antagonist, and a therapeutically effective amount of at least one 5-lipoxygenase inhibitor.

Abstract: This invention discloses novel imidazoles substituted with a six or seven membered heterocyclic ring which contains two nitrogen atoms as part of the heterocyclic ring structure. These compounds have excellent histamine-H3 receptor antagonist activity. Also disclosed are methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy (for example asthma), inflammation, hypertension, raised intraocular pressure (such as glaucoma)—i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypomotility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimer's Disease, schizophrenia, and migraine).

Abstract: The present invention discloses novel N(imidazolylalkyl)-substituted cyclic amine compounds which have excellent histamine-H.sub.3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat allergy, inflammatory and CNS-related diseases.

Abstract: The present invention is directed towards a pharmaceutical composition useful for the treatment of allergic rhinitis, asthma and related disorders. In one embodiment, the composition comprises, in combination, a therapeutically effective amount of at least one neurokinin antagonist, a therapeutically effective amount of at least one H.sub.3 antagonist and a therapeutically effective amount of at least one H.sub.1 antagonist.

Abstract: There is disclosed a method for treating high grade astrocytoma, especially brain stem glioma, in a child by administering to a child in need of such treating an amount of temozolomide sufficient to achieve a clinical response. Preferred dosing schedules are provided.

Abstract: Compounds of formula ##STR1## or pharmaceutically acceptable salts thereof, wherein E, Q, T, U, V, L, Z, X, W, M, Y and Y' are as set forth herein, are described. These compounds are useful as agents in the treatment of allergy, inflammation, autoimmune diseases, B-cell lymphomas, tumors, and the after effects of bone marrow transplantation.

Abstract: There is disclosed a method for treating cancer in a patient in need of such treating comprising administering temozolomide in an amount sufficient to achieve a clinical response wherein the temozolomide is administered more than once per day. Preferred specific dosing schedules are provided.

Abstract: Disclosed are compounds of the formula I wherein:Y represents --CO.sub.2 H, --CO.sub.2 R.sup.6, --C(O)NHR.sup.7, --SO.sub.2 H, --SO.sub.3 H, --SO.sub.3 R.sup.6, --SO.sub.2 NHR.sup.7, --C(O)--N(OH)--R.sup.8, or a group of the formula ##STR1## or a pharmaceutically acceptable addition salt or solvate thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I. Further disclosed is a method for treating or preventing respiratory depression, epileptic seizures or other central nervous system disorders, and for enhancing cognitive performance, by administering an effective amount of a compound of Formula I.

Abstract: A process for preparing a compound of formula (I) ##STR1## wherein R is a methylthio, methylsulfoxy, methylsulfonyl or a nitro group; andX4 is --OH, fluorine or --O--SO.sub.2 R6 where R6 is methyl, trifluoromethyl, phenyl or p-methylphenyl which comprises contacting of a compound of formula (III) ##STR2## where R2 is C.sub.1-4 alkyl; and R and X4 have the above mentioned meanings, with a strong base selected from the group consisting of alkali earth metal alcoholates, alkaline earth metal alcoholates, and tertiary amines in an aprotic solvent, to obtain the compound of formula (I).

Abstract: This invention discloses improved lightpipes for backlighting applications in liquid crystal display devices. The lightpipes comprise transparent polymers with scattering centers. A preferred composition for such lightpipes comprises a cycloolefin polymer containing scattering centers from suitable elastomers and inorganic fillers. The inventive lightpipes offer superior scattering efficiency as well as spatial uniformity of scattering and uniformity of scattering across a wide wavelength range.

Abstract: This invention discloses novel liquid crystal display devices containing polarizers which comprise a liquid crystal polymer and a dichroic absorber. Also disclosed is a process to construct the liquid crystal display devices.

Abstract: Disclosed in this invention is an optical filter to enhance the contrast and brightness of images from a color display. The filter comprises suitable dyes and a polymer matrix, applied in a suitable form on the display unit. Such filters have utility in devices based on CRTs, plasmas and the like.

Abstract: Polymeric compositions having a high transparency, low thermal expansion coefficient and low coefficient of refractive index change with temperature are made from a suitable thermoplastic polymer and index-matched glass or ceramic. Such compositions have utility in optical applications.

Abstract: This invention discloses a thermally expandable composition for use in actuators. The composition contains about 10-50 volume percent hollow glass spheres in a wax or a polymer. The spheres contain a conducting coating affixed thereon. During use in an actuator, the composition is heated to melt the wax or polymer, when the density of the spheres substantially match the density of the melt, thereby substantially eliminating phase separation. The high thermal conductivity of the composition increases the speed of heat transfer out of the composition during the cooling cycles.